La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

UCB Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Jean-Christophe Tellier

Amministratore delegato

€6.7m

Compenso totale

Percentuale dello stipendio del CEO	19.4%
Mandato del CEO	9.8yrs
Proprietà del CEO	n/a
Durata media del management	5.1yrs
Durata media del Consiglio di amministrazione	10.5yrs

Aggiornamenti recenti sulla gestione

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Apr 19

Recent updates

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Sep 10

Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report

Jul 28

Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)

Jul 15

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Apr 19

UCB SA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Jul 31

Is UCB (EBR:UCB) A Risky Investment?

Jun 21

UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 96% Above Its Share Price

May 13

Is UCB (EBR:UCB) Using Too Much Debt?

Mar 18

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jean-Christophe Tellier rispetto agli utili di UCB?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	€240m
Mar 31 2024	n/a	n/a	€292m
Dec 31 2023	€7m	€1m	€343m
Jun 30 2023	n/a	n/a	€332m
Mar 31 2023	n/a	n/a	€376m
Dec 31 2022	€6m	€1m	€420m
Jun 30 2022	n/a	n/a	€887m
Mar 31 2022	n/a	n/a	€971m
Dec 31 2021	€6m	€1m	€1b
Sep 30 2021	n/a	n/a	€996m
Jun 30 2021	n/a	n/a	€936m
Mar 31 2021	n/a	n/a	€834m
Dec 31 2020	€7m	€1m	€732m
Jun 30 2020	n/a	n/a	€743m
Mar 31 2020	n/a	n/a	€767m
Dec 31 2019	€87k	n/a	€790m
Jun 30 2019	n/a	n/a	€652m
Mar 31 2019	n/a	n/a	€722m
Dec 31 2018	€76k	n/a	€792m
Jun 30 2018	n/a	n/a	€872m
Mar 31 2018	n/a	n/a	€812m
Dec 31 2017	€76k	n/a	€752m

Compensazione vs Mercato: La retribuzione totale di Jean-Christophe ($USD 7.41M ) è superiore alla media delle aziende di dimensioni simili nel mercato Belgian ($USD 4.03M ).

Compensazione vs guadagni: La retribuzione di Jean-Christophe è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Jean-Christophe Tellier (65 yo)

9.8yrs

Mandato

€6,662,655

Compensazione

Mr. Jean-Christophe Tellier has been the Chief Executive Officer and Executive Director of UCB SA since January 1, 2015 and April 24, 2014 respectively and also was an Interim Chief Financial Officer since...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jean-Christophe Tellier	CEO & Executive Director	9.8yrs	€6.66m	Nessun dato
Sandrine Dufour	Executive VP	4.3yrs	Nessun dato	Nessun dato
Kirsten Lund-Jurgensen	Executive Vice President of Supply & Technology Solutions	5.1yrs	Nessun dato	Nessun dato
Denelle J. Johnson	Executive VP & General Counsel	1.5yrs	Nessun dato	Nessun dato
Jean-Luc Fleurial	Executive VP & Chief Human Resources Officer	4.7yrs	Nessun dato	Nessun dato
Iris Loew-Friedrich	Executive VP & Chief Medical Officer	16.6yrs	Nessun dato	Nessun dato
Emmanuel Caeymaex	Executive VP & Chief Commercial Officer	9.7yrs	Nessun dato	Nessun dato
Fiona du Monceau	Executive Vice President of Patient Evidence	less than a year	€164.00k	Nessun dato
Caroline Vancoillie	Chief Accounting Officer	11.6yrs	Nessun dato	Nessun dato
Alistair Henry	Executive VP & Chief Scientific Officer	less than a year	Nessun dato	Nessun dato
Antje Witte	Head of Investor Relations	14.8yrs	Nessun dato	Nessun dato
Gwendoline Ornigg	Head of Global Communication	no data	Nessun dato	Nessun dato

5.1yrs

Durata media

58yo

Età media

Gestione esperta: Il team dirigenziale di UCB è esperto e expertise (durata media dell'incarico 5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jean-Christophe Tellier	CEO & Executive Director	10.5yrs	€6.66m	Nessun dato
Gerhard Mayr	Honorary Chairman	no data	€70.00k	Nessun dato
Mark Eyskens	Honorary Chairman	19.8yrs	€15.50k	Nessun dato
Daniel Janssen	Honorary Deputy Chairman	no data	€28.50k	Nessun dato
Georges Jacobs Hagen	Honorary Chairman	no data	€30.00k	Nessun dato
Diégo du de Bergendal	Honorary Chairman	3.5yrs	€87.50k	Nessun dato
Karel Boone	Honorary Chairman	no data	€49.00k	Nessun dato
Dame Davies	Independent Director	10.5yrs	€138.00k	Nessun dato
Jonathan Peacock	Independent Chair of the Board	3.5yrs	€341.83k	Nessun dato
Charles-Antoine Emmanuel Janssen	Director	12.5yrs	€108.50k	Nessun dato
Jonkheer van Rijckevorsel	Director	10.5yrs	€86.00k	Nessun dato
Rodolfo Savitzky	Independent Director	less than a year	Nessun dato	Nessun dato

10.5yrs

Durata media

73yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di UCB è composto da personale esperto e esperto (durata media dell'incarico 10.3 anni).

UCB Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

UCB SA, Annual General Meeting, Apr 27, 2023

UCB SA, Annual General Meeting, Apr 28, 2022

Recent updates

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Consensus EPS estimates increase by 14%

Price target increased by 8.5% to €153

Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report

First half 2024 earnings released: EPS: €1.10 (vs €1.64 in 1H 2023)

Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)

Price target increased by 7.2% to €135

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

UCB SA to Report First Half, 2024 Results on Jul 25, 2024

Dividend of €0.95 announced

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Consensus EPS estimates increase by 18%

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

Is UCB (EBR:UCB) A Risky Investment?

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

Price target increased by 9.4% to €111

Consensus EPS estimates fall by 14%

Earnings Tell The Story For UCB SA (EBR:UCB) As Its Stock Soars 26%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB SA's (EBR:UCB) P/E Is On The Mark

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB (EBR:UCB) Takes On Some Risk With Its Use Of Debt

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

Is UCB (EBR:UCB) Using Too Much Debt?

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

First half 2023 earnings released: EPS: €1.64 (vs €2.10 in 1H 2022)

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?

Upcoming dividend of €0.93 per share at 1.5% yield

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 16%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

First half 2022 earnings released

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

UCB (EBR:UCB) Is Paying Out A Larger Dividend Than Last Year